AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact vaporization of the prostate using the SLT Nd:YAG laser with an MTRL10 6 mm tip under general anaesthesia
Number of subjects: 10
Study 8535679 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact vaporization of the prostate
Number of subjects: 10
Study 8535679 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study 2085581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraset
Number of subjects: 41
Study 2085581 — intervention group
Group type: COMPARATOR
Intervention: Standard spike
Number of subjects: 41
Study 37060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.1 and 0.25 mg in 1 ml solution)
Number of subjects: 8
Study 37060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (protective application before antigen inhalation)
Number of subjects: 8
Study 37060 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular prophylactic application of ipratropium bromide
Number of subjects: 8
Study 37060 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 8
Study 30350896 — intervention group
Group type: EXPERIMENTAL
Intervention: Block periodization (BP)
Number of subjects: 16
Study 30350896 — intervention group
Group type: COMPARATOR
Intervention: Traditional periodization (TRAD)
Number of subjects: 16
Study 28923751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (6 weeks)
Number of subjects: 71
Study 28923751 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-list)
Number of subjects: 71
Study 25730227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery for nonreassuring fetal heart rate (FHR)
Number of subjects: 1291
Study 25730227 — intervention group
Group type: COMPARATOR
Intervention: Control group (labor for 2 hours or longer without cesarean for nonreassuring FHR)
Number of subjects: 1291
Study 23911245 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler flowmetry (LDF)
Number of subjects: 200
Study 21342747 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS followed by sham rTMS
Number of subjects: 45
Study 21342747 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS before any active rTMS
Number of subjects: 45
Study 20530934 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g/day)
Number of subjects: 0
Study 17373090 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day + aggressive debridement
Number of subjects: 504
Study 17373090 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine 250 mg/day alone
Number of subjects: 504
Study 15111485 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (6 micro g/kg) administered subcutaneously once daily
Number of subjects: 13
Study 11813932 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily
Number of subjects: 127
Study 11813932 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% once daily
Number of subjects: 127
Study 11813932 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily (treatment-naive)
Number of subjects: 127
Study 11813932 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% once daily (treatment-naive)
Number of subjects: 127
Study 11813932 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily (previously treated)
Number of subjects: 127
Study 11813932 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% once daily (previously treated)
Number of subjects: 127
Study 11502237 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt-based drink enriched with 1 g plant sterol extracted from soyabean/d
Number of subjects: 30
Study 11502237 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoghurt-based drink enriched with 2 g plant sterols/d
Number of subjects: 30
Study 11502237 — intervention group
Group type: COMPARATOR
Intervention: Low-fat low-lactose yoghurt
Number of subjects: 30
Study 9041099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol (13 to 15 mg per kilogram of body weight per day in divided doses)
Number of subjects: 105
Study 9041099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 9041099 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodiol
Number of subjects: 105
Study 8282745 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited anterior plication (LAP)
Number of subjects: 11
Study 8282745 — intervention group
Group type: COMPARATOR
Intervention: Superficial veins surgery (Group 1)
Number of subjects: 11
Study 3434884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 59
Study 3434884 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 59
Study 1978115 — intervention group
Group type: EXPERIMENTAL
Intervention: L1 (50 mg/kg daily by mouth)
Number of subjects: 26
Study 1978115 — intervention group
Group type: COMPARATOR
Intervention: Desferrioxamine (50 mg/kg daily as a 12 h subcutaneous infusion)
Number of subjects: 26
Study 31213144 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal patient condition
Number of subjects: 249
Study 31213144 — intervention group
Group type: COMPARATOR
Intervention: Depressive patient condition
Number of subjects: 249
Study 29938533 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine (6-week add-on therapy)
Number of subjects: 20
Study 29938533 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment without additional study medication (Control)
Number of subjects: 20
Study 28658582 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute nitrate supplementation (10 mg·kg‐1 body mass of sodium nitrate)
Number of subjects: 11
Study 28658582 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 11
Study 25580630 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 83
Study 23666445 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of ascorbic acid (7.5 g)
Number of subjects: 89
Study 22524083 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.5mg/kg
Number of subjects: 12
Study 22524083 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclofos 70mg/kg
Number of subjects: 12
Study 22524083 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 12
Study 19017773 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based care management for 12 months
Number of subjects: 83
Study 19017773 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 83
Study 17374416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil citrate 50 mg daily for 30 days
Number of subjects: 40
Study 17374416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15504376 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 80
Study 15504376 — intervention group
Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 80
Study 11782329 — intervention group
Group type: COMPARATOR
Intervention: IT fentanyl 25 microg plus normal saline (Group f)
Number of subjects: 48
Study 11782329 — intervention group
Group type: EXPERIMENTAL
Intervention: IT fentanyl 25 microg plus plain bupivacaine 1.25 mg (Group f+pb)
Number of subjects: 48
Study 11782329 — intervention group
Group type: EXPERIMENTAL
Intervention: IT fentanyl 25 microg plus heavy bupivacaine 1.25 mg (Group f+hb)
Number of subjects: 48
Study 9824781 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenously
Number of subjects: 13
Study 9824781 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg orally
Number of subjects: 13
Study 9824781 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenously or 40 mg orally every 12 hours
Number of subjects: 13
Study 8861410 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural treatment including applied relaxation, video self‐modelling, exposure, information, and teaching of hearing tactics
Number of subjects: 20
Study 8861410 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural treatment
Number of subjects: 20
Study 8861410 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 20
Study 2667324 — intervention group
Group type: EXPERIMENTAL
Intervention: epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i.v. once every 3 weeks
Number of subjects: 77
Study 2667324 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil 500 mg/m2 (450 mg/m2 if prior radiotherapy) i.v. once daily for 5 consecutive days every 4 weeks
Number of subjects: 77
Study 1106936 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 mg of naproxen
Number of subjects: 197
Study 1106936 — intervention group
Group type: EXPERIMENTAL
Intervention: 330 mg of naproxen
Number of subjects: 197
Study 30559067 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (systemically administered opioids)
Number of subjects: 44
Study 30559067 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral analgesia (perioperative continuous thoracic paravertebral block with local anesthetic)
Number of subjects: 44
Study 30559067 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral analgesia
Number of subjects: 44
Study 30559067 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 44
Study 27995547 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceptive placebo manipulation
Number of subjects: 75
Study 27995547 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-deceptive placebo manipulation
Number of subjects: 75
Study 27995547 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 27995547 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (deceptive, non-deceptive, control)
Number of subjects: 75
Study 25271378 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 2
Study 25271378 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGlar)
Number of subjects: 2
Study 23647445 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg once daily for 6 months
Number of subjects: 1053
Study 23647445 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care DMTs
Number of subjects: 1053
Study 21596735 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine plus antioxidant vitamins
Number of subjects: 222
Study 21596735 — intervention group
Group type: COMPARATOR
Intervention: Antioxidant vitamins alone
Number of subjects: 222
Study 19806851 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific booklet
Number of subjects: 261
Study 19806851 — intervention group
Group type: COMPARATOR
Intervention: Standard booklet
Number of subjects: 261
Study 17935674 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Number of subjects: 21
Study 15472572 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (5 mg)
Number of subjects: 12
Study 15472572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11427637 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) given as a bolus of 1 mg/kg bodyweight followed by a constant infusion of 0.1 mg/kg bodyweight for 210 min during dialysis
Number of subjects: 41
Study 11427637 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (no intervention)
Number of subjects: 41
Study 9531074 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (0.5 g 8-hourly)
Number of subjects: 393
Study 9531074 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (1 g 8-hourly)
Number of subjects: 393
Study 8028055 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition (TPN)
Number of subjects: 37
Study 8028055 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (TEN)
Number of subjects: 37
Study 8028055 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral plus enteral nutrition (PN/EN)
Number of subjects: 37
Study 8028055 — intervention group
Group type: COMPARATOR
Intervention: All groups (TPN, TEN, PN/EN)
Number of subjects: 37
Study 8028055 — intervention group
Group type: EXPERIMENTAL
Intervention: TEN and PN/EN
Number of subjects: 37
Study 8028055 — intervention group
Group type: COMPARATOR
Intervention: Complications (gastric reflux or abdominal distention)
Number of subjects: 37
Study 8028055 — intervention group
Group type: COMPARATOR
Intervention: Complications (ARDS and respiratory infection)
Number of subjects: 37
Study 2567715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 73
Study 2567715 — intervention group
Group type: COMPARATOR
Intervention: Whole‐ejaculate intracervical insemination (ICI)
Number of subjects: 73
Study 2567715 — intervention group
Group type: COMPARATOR
Intervention: Intercourse after missing inseminations
Number of subjects: 73
Study 2567715 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI) for male factor (MF) patients
Number of subjects: 73
Study 30911756 — intervention group
Group type: COMPARATOR
Intervention: 2× daily feeding (half ration at 0730 and 1530 h)
Number of subjects: 177
Study 30911756 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× daily feeding (a third portion at 0730, 1130, and 1530 h)
Number of subjects: 177
Study 30911756 — intervention group
Group type: EXPERIMENTAL
Intervention: 2× daily feeding
Number of subjects: 177
Study 30911756 — intervention group
Group type: EXPERIMENTAL
Intervention: 3× daily feeding
Number of subjects: 177
Study 28760664 — intervention group
Group type: EXPERIMENTAL
Intervention: 10ppm OHA
Number of subjects: 4
Study 28760664 — intervention group
Group type: EXPERIMENTAL
Intervention: 20ppm OHA
Number of subjects: 4
Study 28760664 — intervention group
Group type: COMPARATOR
Intervention: Control (no OHA)
Number of subjects: 4
Study 28760664 — intervention group
Group type: EXPERIMENTAL
Intervention: R (water from 20 OHA group, no OHA)
Number of subjects: 4
Study 26603186 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Advanced Home Care and Heart Failure Care intervention
Number of subjects: 72
Study 26603186 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by a primary health care center or heart failure clinic
Number of subjects: 72
Study 24178238 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 h) applied for 24 h
Number of subjects: 48
Study 22103674 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% and benzoyl peroxide 2.5% (A-BPO)
Number of subjects: 0
Study 22103674 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 20031846 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty reduction intervention (provided in 5 clinics) including access to a specially designed study form with blood pressure graphs, assessment checkboxes, and a menu of services (24-hour ambulatory blood pressure monitoring, electronic bottle cap assessment of medication adherence, lifestyle assessment and counseling).
Number of subjects: 680
Study 20031846 — intervention group
Group type: COMPARATOR
Intervention: Usual care (provided in 5 clinics) without access to the intervention services.
Number of subjects: 680
Study 20031846 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty reduction intervention
Number of subjects: 680
Study 20031846 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 680
Study 17802891 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Denshen Pilulae, 10# tid for 2 weeks
Number of subjects: 24
Study 14977388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 microg once daily
Number of subjects: 0
Study 14977388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg once daily
Number of subjects: 0
Study 14977388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg daily
Number of subjects: 0
Study 14977388 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 microg daily
Number of subjects: 0
Study 14977388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide 80 or 320 microg daily
Number of subjects: 0
Study 14977388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Number of subjects: 0
Study 11194406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartar-control mouthrinse containing zinc chloride
Number of subjects: 334
Study 11194406 — intervention group
Group type: COMPARATOR
Intervention: Tartar-control dentifrice containing pyrophosphate (positive control)
Number of subjects: 334
Study 11194406 — intervention group
Group type: COMPARATOR
Intervention: Regular dentifrice and antiseptic rinse (negative control)
Number of subjects: 334
Study 9741504 — intervention group
Group type: EXPERIMENTAL
Intervention: Any atenolol
Number of subjects: 40844
Study 9741504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous and oral atenolol
Number of subjects: 40844
Study 9741504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol
Number of subjects: 40844
Study 9741504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral atenolol
Number of subjects: 40844
Study 9741504 — intervention group
Group type: COMPARATOR
Intervention: No atenolol
Number of subjects: 40844
Study 7991337 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction of experiences in the same context
Number of subjects: 20
Study 7991337 — intervention group
Group type: COMPARATOR
Intervention: Reconstruction of experiences outside of the context
Number of subjects: 20
Study 2543999 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 8
Study 2543999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31577520 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine supplementation (5g) with resistance training (RT)
Number of subjects: 36
Study 31577520 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation with resistance training (RT)
Number of subjects: 36
Study 30552406 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose rosuvastatin
Number of subjects: 732
Study 30552406 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 732
Study 30552406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 732
Study 30552406 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan + Low-dose rosuvastatin
Number of subjects: 732
Study 30552406 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Low-dose rosuvastatin
Number of subjects: 732
Study 28322748 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT)
Number of subjects: 0
Study 28322748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24585100 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM allergen extract for SLIT
Number of subjects: 72
Study 24585100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 23801303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 45 mg/day plus fulvestrant
Number of subjects: 62
Study 23801303 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 62
Study 20683084 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking intervention
Number of subjects: 148
Study 20683084 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treatment
Number of subjects: 148
Study 20683084 — intervention group
Group type: COMPARATOR
Intervention: Objective crime measures
Number of subjects: 148
Study 19038708 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet concentrate (PC)
Number of subjects: 108
Study 19038708 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone plug (BP)
Number of subjects: 108
Study 19038708 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study 19038708 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PC and BP
Number of subjects: 108
Study 15923042 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy 10-30 mg daily
Number of subjects: 34
Study 15923042 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy 5-20 mg daily
Number of subjects: 34
Study 15923042 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined fluoxetine plus olanzapine therapy 10-40 mg plus 5-15 mg daily
Number of subjects: 34
Study 15923042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 12822744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (n = 26)
Number of subjects: 53
Study 12822744 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 27)
Number of subjects: 53
Study 12822744 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 53
Study 10693711 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 and nonionic contrast material
Number of subjects: 40
Study 10693711 — intervention group
Group type: COMPARATOR
Intervention: CO2 alone
Number of subjects: 40
Study 10693711 — intervention group
Group type: COMPARATOR
Intervention: CO2 and gadodiamide
Number of subjects: 40
Study 10693711 — intervention group
Group type: COMPARATOR
Intervention: CO2 and nonionic contrast material vs CO2 alone and gadodiamide
Number of subjects: 40
Study 10693711 — intervention group
Group type: COMPARATOR
Intervention: CO2 and nonionic contrast material vs CO2 and gadodiamide
Number of subjects: 40
Study 8794412 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemo-immunotherapy (IL-2 and LAK cells after two courses of anticancer chemotherapy)
Number of subjects: 82
Study 8794412 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant therapy)
Number of subjects: 82
Study 8794412 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (same anticancer chemotherapy as group A)
Number of subjects: 82
Study 8392151 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine without aura (MO)
Number of subjects: 193
Study 8392151 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with aura (MA)
Number of subjects: 193
Study 8392151 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 193
Study 3522507 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (3.3 g/day in two divided doses for 12 weeks)
Number of subjects: 0
Study 3522507 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for 12 weeks)
Number of subjects: 0
Study 31232197 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 5